Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SUN PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
SUN PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,072 | 328 | - | |
Low | Rs | 790 | 236 | - | |
Sales per share (Unadj.) | Rs | 182.9 | 97.5 | - | |
Earnings per share (Unadj.) | Rs | 35.7 | -24.6 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | -20.4 | - | |
Dividends per share (Unadj.) | Rs | 11.50 | 0 | - | |
Avg Dividend yield | % | 1.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 233.4 | 76.5 | - | |
Shares outstanding (eoy) | m | 2,399.34 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.1 | 2.9 | 175.9% | |
Avg P/E ratio | x | 26.1 | -11.5 | -227.2% | |
P/CF ratio (eoy) | x | 20.1 | -13.9 | -145.3% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 108.2% | |
Dividend payout | % | 32.2 | 0 | - | |
Avg Mkt Cap | Rs m | 2,233,361 | 47,604 | 4,691.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 82,960 | 2,988 | 2,776.7% | |
Avg. sales/employee | Rs Th | 0 | 3,832.5 | - | |
Avg. wages/employee | Rs Th | 0 | 696.0 | - | |
Avg. net profit/employee | Rs Th | 0 | -965.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 438,857 | 16,453 | 2,667.4% | |
Other income | Rs m | 8,199 | 115 | 7,115.8% | |
Total revenues | Rs m | 447,055 | 16,568 | 2,698.3% | |
Gross profit | Rs m | 112,900 | -2,851 | -3,959.8% | |
Depreciation | Rs m | 25,294 | 710 | 3,562.1% | |
Interest | Rs m | 1,720 | 446 | 385.9% | |
Profit before tax | Rs m | 94,084 | -3,892 | -2,417.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 8,476 | 243 | 3,485.5% | |
Profit after tax | Rs m | 85,608 | -4,146 | -2,065.0% | |
Gross profit margin | % | 25.7 | -17.3 | -148.5% | |
Effective tax rate | % | 9.0 | -6.2 | -144.2% | |
Net profit margin | % | 19.5 | -25.2 | -77.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398,619 | 12,050 | 3,308.0% | |
Current liabilities | Rs m | 199,064 | 6,780 | 2,936.0% | |
Net working cap to sales | % | 45.5 | 32.0 | 142.0% | |
Current ratio | x | 2.0 | 1.8 | 112.7% | |
Inventory Days | Days | 147 | 111 | 132.6% | |
Debtors Days | Days | 95 | 124 | 76.8% | |
Net fixed assets | Rs m | 376,960 | 7,024 | 5,366.7% | |
Share capital | Rs m | 2,399 | 76 | 3,140.9% | |
Net worth | Rs m | 559,954 | 12,914 | 4,336.1% | |
Long term debt | Rs m | 0 | 4,538 | 0.0% | |
Total assets | Rs m | 775,794 | 24,395 | 3,180.1% | |
Interest coverage | x | 55.7 | -7.7 | -720.4% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 83.9% | |
Return on assets | % | 11.3 | -15.2 | -74.2% | |
Return on equity | % | 15.3 | -32.1 | -47.6% | |
Return on capital | % | 17.1 | -19.8 | -86.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49,593 | 1,404 | 3,531.4% | |
From Investments | Rs m | -79,437 | -431 | 18,421.9% | |
From Financial Activity | Rs m | 23,761 | 4,119 | 576.9% | |
Net Cashflow | Rs m | 1,155 | 5,092 | 22.7% |
Compare SUN PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SUN PHARMA With: TYCHE INDUSTRIES NEULAND LABS SOURCE NATURAL FOODS PLETHICO PHARMA ALCHEMIST LIMITED
Indian share markets pared losses as the session progressed but still ended lower.